Developer docs
API playgroundTry for free, no card

Search company profiles

Solasia Pharma

Full company profile

uuid003dbn1

Namestring
Solasia Pharma
Legal namestring
Solasia Pharma K.K.
Websiteurl
solasia.co.jp
Company typeenum
Public
Founded yearint
2006
Descriptiontext

Solasia Pharma K.K. (TSE Growth: 4597) is a Tokyo-headquartered specialty pharmaceutical company founded in 2006 that in-licenses oncology and oncology-supportive-care drug candidates and advances them through clinical development and regulatory approval for commercialization in Japan, China, Korea, and select other Asian and South American markets. The commercial portfolio comprises three assets: episil oral liquid, a FluidCrystal-licensed medical device for oral mucositis pain relief; DARVIAS (darinaparsin), an organoarsenic antineoplastic agent approved in Japan for relapsed/refractory peripheral T-cell lymphoma with orphan designation in the US and Europe; and Sancuso, a transdermal granisetron patch for chemotherapy-induced nausea and vomiting launched in China in 2019. The development pipeline includes SP-04 (PledOx) for chemotherapy-induced peripheral neuropathy in nonclinical stage and SP-05 (arfolitixorin) for colorectal cancer with development resumed in March 2024, alongside early-stage nucleic-acid (RECQL1-siRNA) and RNA-editing (PPR platform with EditForce) research collaborations.

The business operates on an in-licensing model: Solasia acquires regional or worldwide development and commercialization rights from originator biotech firms (Camurus, Isofol, PledPharma/Egetis, Alaunos, GeneCare, EditForce), runs clinical development and NDA programs, and then commercializes the assets through exclusive regional partners—Meiji Seika Pharma and Nippon Kayaku in Japan, Lee's Pharmaceutical and Changchun GeneScience in China, Synex in Korea, Maruho in Japan for SP-04, HB Human BioScience across much of Latin America, Daiichi Sankyo Brasil in Brazil, and MAAB Pharma in greater China for Sancuso. Revenue is generated through product sales, signing/contract upfront fees, development and commercial milestone payments from licensees, and ongoing royalties on partner sales.

With a headcount of approximately 27 employees (21 in Japan and 6 in China via its wholly-owned Shanghai subsidiary, Solasia Medical Information Consulting (Shanghai) Co. Ltd.), the company positions itself as a small, focused team addressing unmet needs in oncology and cancer supportive care across Asia. Operating losses have been persistent, reflecting sustained investment in clinical development and pipeline expansion, and the company continues to broaden its commercial footprint through new regional partnerships and incremental product launches.

Short descriptiontext

Solasia Pharma K.K. is a Tokyo-based specialty pharmaceutical company that in-licenses oncology and supportive-care drug candidates, develops them through clinical and regulatory stages, and commercializes them in Asia and select South American markets through exclusive regional partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMinato, Japan
HQ citystring
Minato
HQ countrystring
Japan
HQ regionstring
Asia
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
oncology pharmaceuticals, specialty pharma in-licensing, supportive care oncology, prescription cancer drugs, medical device oncology
Industry3 codes
PRIMARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAN
Pain Management & Anesthesiology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAE
Gastroenterology Specialty Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing32541
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Specialty Oncology Pharmaceuticals
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model5 records
1Product Sales
TypeHardware Sales
Description

Direct revenue from sales of commercialized pharmaceutical products and medical devices including episil oral liquid, DARVIAS injection, and Sancuso in respective markets (Japan, China, Korea).

solasia.co.jp
2Signing Fee / Contract Upfront
TypeLicensing Royalties
Description

One-time payments received when out-licensing agreements are signed with regional partners for commercialization rights in specific territories.

solasia.co.jp
3Development Milestones
TypeLicensing Royalties
Description

One-time payments triggered by achievement of specific development milestones such as clinical trial phases, regulatory submissions, and approvals.

solasia.co.jp
4Commercial Milestones
TypeLicensing Royalties
Description

One-time payments when licensees achieve certain predefined product sales targets in their respective territories.

solasia.co.jp
5Royalties
TypeLicensing Royalties
Description

Ongoing royalty payments based on product sales revenue generated by licensees in their respective territories.

solasia.co.jp
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1DARVIAS
Description

Antineoplastic agent for relapsed or refractory peripheral T-cell lymphoma (PTCL). Generic name: Darinaparsin.

solasia.co.jp
+2 more records
Core offering1 text field

Solasia Pharma is a specialty pharmaceutical company that in-licenses oncology drug candidates and medical devices, advances them through clinical development and regulatory approval in Asia, and commercializes them through regional distribution partners. Its commercial portfolio includes episil oral liquid (a Camurus FluidCrystal-based medical device for oral mucositis pain), DARVIAS injection (darinaparsin for relapsed/refractory PTCL), and Sancuso (a transdermal granisetron patch for chemotherapy-induced nausea and vomiting).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • episil provides pain relief lasting approximately 8 hours after single application
+1 more record
Product overview1 text field

Solasia Pharma is a specialty pharmaceutical company focused on oncology, offering a portfolio of commercialized pharmaceutical products and medical devices, along with a pipeline of development-stage candidates. Commercial products include: (1) episil® oral liquid - a medical device for oral mucositis pain relief; (2) DARVIAS® Injection 135mg - a prescription drug for peripheral T-cell lymphoma; and (3) Sancuso® - a transdermal patch for chemotherapy-induced nausea and vomiting. The pipeline includes SP-04 for chemotherapy-induced peripheral neuropathy and SP-05 for colorectal cancer. The company also has early-stage research projects including a RECQL1-siRNA nucleic acid drug candidate and an RNA editing technology project. Products are commercialized through regional partners including Meiji Seika Pharma (Japan), Lee's Pharm (China), Synex (Korea), and Nippon Kayaku (Japan for DARVIAS).

Product and service3 records
1episil oral liquid (SP-03)
CategoryMedical Device
Description

A non-absorptive liquid medical device that forms a protective film on oral mucosa within minutes to provide approximately 8 hours of pain relief for oral mucositis caused by chemotherapy and radiotherapy. Developed using Camurus's proprietary FluidCrystal technology. Sold to hospitals and oncology centers via regional commercialization partners (Meiji Seika in Japan, Synex in South Korea, Changchun GeneScience in China).

2DARVIAS Injection 135mg (SP-02)
CategoryPrescription Drug
Description

An antineoplastic agent containing darinaparsin, an organoarsenic compound with anticancer activity, indicated for relapsed or refractory peripheral T-cell lymphoma (PTCL). Works by disrupting mitochondrial function, increasing reactive oxygen species production, and inducing cell cycle arrest and apoptosis. Has received orphan drug designation in the US and Europe for PTCL. Sold to hematology/oncology specialists and hospitals via Nippon Kayaku in Japan and HB Human BioScience in South America.

3Sancuso (SP-01)
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership16 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2022-07-08
Description

Solasia acquired the episil oral liquid business worldwide from Camurus on July 8, 2022, obtaining assets and licensing rights to develop, manufacture, and commercialize the product globally. Transition includes assistance period from Camurus until May 2024.

2Meiji Seika Pharma Co., Ltd.
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Exclusive commercialization and promotion partner for episil oral liquid in Japan. Product approved July 2017, launched May 2018.

solasia.co.jp
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Sales promotion partner for Sancuso in China. Holds exclusive sales rights for China (excluding Beijing, Shanghai, Guangzhou, Hong Kong, Macau, Taiwan). Product approved July 2018, launched March 2019.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Exclusive commercialization partner for episil oral liquid in South Korea. Product approved October 2019, launched September 2020.

5Nippon Kayaku Co., Ltd.
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Commercialization and promotion partner for DARVIAS injection 135mg in Japan. Product approved June 2022, launched August 2022.

solasia.co.jp
Strategic tierMajorTypeChannel Partner/ Reseller/ Distributor
Description

Exclusive license for darinaparsin (SP-02) in South America (Colombia, Peru, Ecuador, Venezuela, Chile, Panama, Costa Rica, Guatemala). Colombia and Peru NDA filings completed based on Japan approval.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Solasia acquired worldwide rights to darinaparsin (SP-02) from Alaunos Therapeutics. Original Asia-Pacific rights obtained March 2011, expanded to global rights July 2014.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Solasia acquired exclusive development and commercialization rights for arfolitixorin (SP-05) in Japan from Isofol Medical AB in August 2020. Phase III trial ended November 2022 (primary endpoints not met), development resumed March 2024.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Solasia acquired exclusive development and commercialization rights for PledOx (SP-04) for Japan, China (including Hong Kong, Macau), South Korea, and Taiwan in November 2017. Partner Maruho for Japan commercialization.

10Maruho Co., Ltd.
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Exclusive commercialization partner for PledOx (SP-04) in Japan for chemotherapy-induced peripheral neuropathy (CIPN). License agreement signed December 2019.

solasia.co.jp
Strategic tierStrategicTypeStrategic or Co-development Partner
Description

Option agreement for worldwide rights to RECQL1-siRNA, a nucleic acid drug candidate for peritoneal metastases. Development targeting various gastrointestinal cancers and ovarian cancer.

Strategic tierStrategicTypeStrategic or Co-development Partner
Description

Joint R&D agreement for new drug candidates based on RNA editing technology using PPR (pentatricopeptide repeat) protein platform. Focus on rare diseases and oncology applications.

13Changchun GeneScience Pharmaceutical Co., Ltd.
Strategic tierMajorTypeChannel Partner/ Reseller/ Distributor
Description

Sales activities for episil oral liquid in China since March 2025. License agreement December 2024 for exclusive commercialization rights in China.

solasia.co.jp
Strategic tierCoreTypeTechnology or Integration
Description

Original licensor for Sancuso (SP-01) rights from Strakan International Ltd. (now Kyowa Kirin Services Limited) in May 2008 for Japan, China, and Asian territories. Rights for China region transferred to Kyowa Kirin International UK NewCo Limited in February 2024.

15MAAB Pharma Limited
Strategic tierMajorTypeChannel Partner/ Reseller/ Distributor
Description

License agreement January 2026 for exclusive sales rights for Sancuso in China region (mainland China, Hong Kong, Macau, Taiwan).

news.cision.com
16Daiichi Sankyo Brasil Farmaceutica Ltda.
Strategic tierMajorTypeChannel Partner/ Reseller/ Distributor
Description

Exclusive commercialization rights for episil in Brazil. License agreement August 2025 with Daiichi Sankyo's 100% subsidiary.

news.cision.com
Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Swedish specialty pharma developing products based on FluidCrystal technology. Solasia in-licensed and ultimately acquired worldwide rights to episil oral liquid from Camurus in July 2022. Strong technology and partnership overlap.

2Sosei Group / Nxera Pharma
TypeDirect peer
Description

Japanese specialty pharma that grows through in-licensing and acquisitions of development-stage drug candidates. Solasia's CFO previously held VP Corporate Planning role at Sosei. Strong business model comparability in-licensing-driven growth.

3Zeria Pharmaceutical Co., Ltd.
TypeDirect peer
Description

Japanese specialty pharmaceutical company that develops and markets prescription drugs with focus on gastroenterology, oncology supportive care, and rare diseases. Similar specialty-pharma positioning in Japan with comparable pipeline depth and partner-driven commercialization strategy.

TypeBroad incumbent
Description

Major Japanese oncology-focused pharmaceutical company (Otsuka subsidiary) that develops and markets chemotherapy agents, supportive-care drugs, and oral mucositis treatments. Comparable in oncology specialization and Japan-Asia commercial reach, but at much larger scale than Solasia.

5AnGes, Inc.
TypeDirect peer
Description

Japanese specialty biotech/pharma developing gene therapies and innovative treatments. Listed on TSE Growth market similar to Solasia. Comparable as Japan-listed specialty pharma with small capitalization and development-stage pipeline.

6Mochida Pharmaceutical Co., Ltd.
TypeDirect peer
Description

Mid-cap Japanese specialty pharma with focus on specialty therapeutic areas including oncology and rare diseases. Comparable in scale, product portfolio breadth, and Japan-domestic commercialization model.

TypeRegional player
Description

Hong Kong-listed specialty pharma operating primarily in Greater China. Solasia's commercialization partner for Sancuso across China and Asia. Both focus on specialty therapeutics distribution in Asia with partner-driven models.

TypeDirect peer
Description

Japanese specialty biotech focused on oncology and infectious disease therapeutics. Solasia's Head of Marketing previously held senior positions at Oncolys. Comparable as small Japan-based specialty company with oncology therapeutic focus.

TypeDirect peer
Description

Japanese specialty pharma with similar small-team in-licensing model focused on developing innovative therapeutics. Solasia's former CFO Toshio Miyashita served as J-Pharma's CFO before joining Solasia. Compares on business model (asset-light in-licensing, oncology focus) and geographic footprint (Japan/Asia).

TypeEmerging player
Description

Swedish biotech that developed arfolitixorin (SP-05), the very compound Solasia in-licensed for Japan. Direct counterparty in the partnership, focused on folate-based oncology therapeutics. Same molecule, different geography.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles16 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Solasia Pharma

Specialty Oncology Pharmaceuticalssolasia.co.jp

Solasia Pharma K.K. is a Tokyo-based specialty pharmaceutical company that in-licenses oncology and supportive-care drug candidates, develops them through clinical and regulatory stages, and commercializes them in Asia and select South American markets through exclusive regional partners.

What Solasia Pharma does

Solasia Pharma K.K. (TSE Growth: 4597) is a Tokyo-headquartered specialty pharmaceutical company founded in 2006 that in-licenses oncology and oncology-supportive-care drug candidates and advances them through clinical development and regulatory approval for commercialization in Japan, China, Korea, and select other Asian and South American markets. The commercial portfolio comprises three assets: episil oral liquid, a FluidCrystal-licensed medical device for oral mucositis pain relief; DARVIAS (darinaparsin), an organoarsenic antineoplastic agent approved in Japan for relapsed/refractory peripheral T-cell lymphoma with orphan designation in the US and Europe; and Sancuso, a transdermal granisetron patch for chemotherapy-induced nausea and vomiting launched in China in 2019. The development pipeline includes SP-04 (PledOx) for chemotherapy-induced peripheral neuropathy in nonclinical stage and SP-05 (arfolitixorin) for colorectal cancer with development resumed in March 2024, alongside early-stage nucleic-acid (RECQL1-siRNA) and RNA-editing (PPR platform with EditForce) research collaborations.

The business operates on an in-licensing model: Solasia acquires regional or worldwide development and commercialization rights from originator biotech firms (Camurus, Isofol, PledPharma/Egetis, Alaunos, GeneCare, EditForce), runs clinical development and NDA programs, and then commercializes the assets through exclusive regional partners—Meiji Seika Pharma and Nippon Kayaku in Japan, Lee's Pharmaceutical and Changchun GeneScience in China, Synex in Korea, Maruho in Japan for SP-04, HB Human BioScience across much of Latin America, Daiichi Sankyo Brasil in Brazil, and MAAB Pharma in greater China for Sancuso. Revenue is generated through product sales, signing/contract upfront fees, development and commercial milestone payments from licensees, and ongoing royalties on partner sales.

With a headcount of approximately 27 employees (21 in Japan and 6 in China via its wholly-owned Shanghai subsidiary, Solasia Medical Information Consulting (Shanghai) Co. Ltd.), the company positions itself as a small, focused team addressing unmet needs in oncology and cancer supportive care across Asia. Operating losses have been persistent, reflecting sustained investment in clinical development and pipeline expansion, and the company continues to broaden its commercial footprint through new regional partnerships and incremental product launches.

Solasia Pharma firmographics

Firmographics
Name
Solasia Pharma
Legal name
Solasia Pharma K.K.
Website
https://solasia.co.jp
Company type
Public
Founded year
2006
Operating status
Operating
Headcount range
11–50 employees
Short description
Solasia Pharma K.K. is a Tokyo-based specialty pharmaceutical company that in-licenses oncology and supportive-care drug candidates, develops them through clinical and regulatory stages, and commercializes them in Asia and select South American markets through exclusive regional partners.
Ownership category
akta.pro rank

Solasia Pharma industry classification

Industry
Product category
Specialty Oncology Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAN
Pain Management & Anesthesiology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAE
Gastroenterology Specialty Pharmaceuticals

Keywords

  • Oncology pharmaceuticals
  • Specialty pharma in-licensing
  • Supportive care oncology
  • Prescription cancer drugs
  • Medical device oncology

Where Solasia Pharma is headquartered

Location

Headquarters

HQ city
Minato
HQ country
Japan
HQ region
Asia

Offices3 records

Markets served

Solasia Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations

Revenue model

  1. Product Sales: Direct revenue from sales of commercialized pharmaceutical products and medical devices including episil oral liquid, DARVIAS injection, and Sancuso in respective markets (Japan, China, Korea).
  2. Signing Fee / Contract Upfront: One-time payments received when out-licensing agreements are signed with regional partners for commercialization rights in specific territories.
  3. Development Milestones: One-time payments triggered by achievement of specific development milestones such as clinical trial phases, regulatory submissions, and approvals.
  4. Commercial Milestones: One-time payments when licensees achieve certain predefined product sales targets in their respective territories.
  5. Royalties: Ongoing royalty payments based on product sales revenue generated by licensees in their respective territories.

Go-to-market motion2 records

Distribution channels6 records

Marketing channels4 records

Solasia Pharma product offering

Product offering

Core offering

Solasia Pharma is a specialty pharmaceutical company that in-licenses oncology drug candidates and medical devices, advances them through clinical development and regulatory approval in Asia, and commercializes them through regional distribution partners. Its commercial portfolio includes episil oral liquid (a Camurus FluidCrystal-based medical device for oral mucositis pain), DARVIAS injection (darinaparsin for relapsed/refractory PTCL), and Sancuso (a transdermal granisetron patch for chemotherapy-induced nausea and vomiting).

Product overview

Solasia Pharma is a specialty pharmaceutical company focused on oncology, offering a portfolio of commercialized pharmaceutical products and medical devices, along with a pipeline of development-stage candidates. Commercial products include: (1) episil® oral liquid - a medical device for oral mucositis pain relief; (2) DARVIAS® Injection 135mg - a prescription drug for peripheral T-cell lymphoma; and (3) Sancuso® - a transdermal patch for chemotherapy-induced nausea and vomiting. The pipeline includes SP-04 for chemotherapy-induced peripheral neuropathy and SP-05 for colorectal cancer. The company also has early-stage research projects including a RECQL1-siRNA nucleic acid drug candidate and an RNA editing technology project. Products are commercialized through regional partners including Meiji Seika Pharma (Japan), Lee's Pharm (China), Synex (Korea), and Nippon Kayaku (Japan for DARVIAS).

Differentiator

Problem solved

Functional benefit

Brands

  • DARVIAS: Antineoplastic agent for relapsed or refractory peripheral T-cell lymphoma (PTCL). Generic name: Darinaparsin.
  • episil
  • Sancuso

Products and services

  • episil oral liquid (SP-03) A non-absorptive liquid medical device that forms a protective film on oral mucosa within minutes to provide approximately 8 hours of pain relief for oral mucositis caused by chemotherapy and radiotherapy. Developed using Camurus's proprietary FluidCrystal technology. Sold to hospitals and oncology centers via regional commercialization partners (Meiji Seika in Japan, Synex in South Korea, Changchun GeneScience in China).
  • DARVIAS Injection 135mg (SP-02) An antineoplastic agent containing darinaparsin, an organoarsenic compound with anticancer activity, indicated for relapsed or refractory peripheral T-cell lymphoma (PTCL). Works by disrupting mitochondrial function, increasing reactive oxygen species production, and inducing cell cycle arrest and apoptosis. Has received orphan drug designation in the US and Europe for PTCL. Sold to hematology/oncology specialists and hospitals via Nippon Kayaku in Japan and HB Human BioScience in South America.
  • Sancuso (SP-01)

Quantifiable outcome

  • episil provides pain relief lasting approximately 8 hours after single application
  • +1 more outcomes

Companies that use Solasia Pharma

Customer profile

Named customers5 records

Segments2 records

Ideal customer profiles3 records

Solasia Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Solasia Pharma partnerships and signals

Strategic signal

Partnerships

16 partnerships are on record, tiered core, major and strategic.

  • Camurus ABcoreTechnology or Integration · 8 July 2022Solasia acquired the episil oral liquid business worldwide from Camurus on July 8, 2022, obtaining assets and licensing rights to develop, manufacture, and commercialize the product globally. Transition includes assistance period from Camurus until May 2024.
  • Meiji Seika Pharma Co., Ltd.coreChannel Partner/ Reseller/ DistributorExclusive commercialization and promotion partner for episil oral liquid in Japan. Product approved July 2017, launched May 2018.
  • Lee's Pharmaceutical (HK) LimitedcoreChannel Partner/ Reseller/ DistributorSales promotion partner for Sancuso in China. Holds exclusive sales rights for China (excluding Beijing, Shanghai, Guangzhou, Hong Kong, Macau, Taiwan). Product approved July 2018, launched March 2019.
  • SynexcoreChannel Partner/ Reseller/ DistributorExclusive commercialization partner for episil oral liquid in South Korea. Product approved October 2019, launched September 2020.
  • Nippon Kayaku Co., Ltd.coreChannel Partner/ Reseller/ DistributorCommercialization and promotion partner for DARVIAS injection 135mg in Japan. Product approved June 2022, launched August 2022.
  • HB Human BioScience SASmajorChannel Partner/ Reseller/ DistributorExclusive license for darinaparsin (SP-02) in South America (Colombia, Peru, Ecuador, Venezuela, Chile, Panama, Costa Rica, Guatemala). Colombia and Peru NDA filings completed based on Japan approval.
  • Alaunos Therapeutics (formerly ZIOPHARM Oncology)coreStrategic or Co-development PartnerSolasia acquired worldwide rights to darinaparsin (SP-02) from Alaunos Therapeutics. Original Asia-Pacific rights obtained March 2011, expanded to global rights July 2014.
  • Isofol Medical ABmajorStrategic or Co-development PartnerSolasia acquired exclusive development and commercialization rights for arfolitixorin (SP-05) in Japan from Isofol Medical AB in August 2020. Phase III trial ended November 2022 (primary endpoints not met), development resumed March 2024.
  • PledPharma AB (now Egetis Therapeutics AB)majorStrategic or Co-development PartnerSolasia acquired exclusive development and commercialization rights for PledOx (SP-04) for Japan, China (including Hong Kong, Macau), South Korea, and Taiwan in November 2017. Partner Maruho for Japan commercialization.
  • Maruho Co., Ltd.coreChannel Partner/ Reseller/ DistributorExclusive commercialization partner for PledOx (SP-04) in Japan for chemotherapy-induced peripheral neuropathy (CIPN). License agreement signed December 2019.
  • GeneCare Research Institute Co., Ltd.strategicStrategic or Co-development PartnerOption agreement for worldwide rights to RECQL1-siRNA, a nucleic acid drug candidate for peritoneal metastases. Development targeting various gastrointestinal cancers and ovarian cancer.
  • EditForce Inc.strategicStrategic or Co-development PartnerJoint R&D agreement for new drug candidates based on RNA editing technology using PPR (pentatricopeptide repeat) protein platform. Focus on rare diseases and oncology applications.
  • Changchun GeneScience Pharmaceutical Co., Ltd.majorChannel Partner/ Reseller/ DistributorSales activities for episil oral liquid in China since March 2025. License agreement December 2024 for exclusive commercialization rights in China.
  • Kyowa Kirin Services Limited (formerly Strakan/ProStrakan)coreTechnology or IntegrationOriginal licensor for Sancuso (SP-01) rights from Strakan International Ltd. (now Kyowa Kirin Services Limited) in May 2008 for Japan, China, and Asian territories. Rights for China region transferred to Kyowa Kirin International UK NewCo Limited in February 2024.
  • MAAB Pharma LimitedmajorChannel Partner/ Reseller/ DistributorLicense agreement January 2026 for exclusive sales rights for Sancuso in China region (mainland China, Hong Kong, Macau, Taiwan).
  • Daiichi Sankyo Brasil Farmaceutica Ltda.majorChannel Partner/ Reseller/ DistributorExclusive commercialization rights for episil in Brazil. License agreement August 2025 with Daiichi Sankyo's 100% subsidiary.

Scale indicators4 records

Recent moves9 records

Expansion highlights6 records

Solasia Pharma competitors and assessment

Company assessment

Emerging players

  • Camurus AB: Swedish specialty pharma developing products based on FluidCrystal technology. Solasia in-licensed and ultimately acquired worldwide rights to episil oral liquid from Camurus in July 2022. Strong technology and partnership overlap.
  • Isofol Medical AB: Swedish biotech that developed arfolitixorin (SP-05), the very compound Solasia in-licensed for Japan. Direct counterparty in the partnership, focused on folate-based oncology therapeutics. Same molecule, different geography.

Direct peers

  • Sosei Group / Nxera Pharma: Japanese specialty pharma that grows through in-licensing and acquisitions of development-stage drug candidates. Solasia's CFO previously held VP Corporate Planning role at Sosei. Strong business model comparability in-licensing-driven growth.
  • Zeria Pharmaceutical Co., Ltd. Japanese specialty pharmaceutical company that develops and markets prescription drugs with focus on gastroenterology, oncology supportive care, and rare diseases. Similar specialty-pharma positioning in Japan with comparable pipeline depth and partner-driven commercialization strategy.
  • AnGes, Inc. Japanese specialty biotech/pharma developing gene therapies and innovative treatments. Listed on TSE Growth market similar to Solasia. Comparable as Japan-listed specialty pharma with small capitalization and development-stage pipeline.
  • Mochida Pharmaceutical Co., Ltd. Mid-cap Japanese specialty pharma with focus on specialty therapeutic areas including oncology and rare diseases. Comparable in scale, product portfolio breadth, and Japan-domestic commercialization model.
  • Oncolys BioPharma Inc. Japanese specialty biotech focused on oncology and infectious disease therapeutics. Solasia's Head of Marketing previously held senior positions at Oncolys. Comparable as small Japan-based specialty company with oncology therapeutic focus.
  • J-Pharma Co., Ltd. Japanese specialty pharma with similar small-team in-licensing model focused on developing innovative therapeutics. Solasia's former CFO Toshio Miyashita served as J-Pharma's CFO before joining Solasia. Compares on business model (asset-light in-licensing, oncology focus) and geographic footprint (Japan/Asia).

Broad incumbents

  • Taiho Pharmaceutical: Major Japanese oncology-focused pharmaceutical company (Otsuka subsidiary) that develops and markets chemotherapy agents, supportive-care drugs, and oral mucositis treatments. Comparable in oncology specialization and Japan-Asia commercial reach, but at much larger scale than Solasia.

Regional players

  • Lee's Pharmaceutical Holdings: Hong Kong-listed specialty pharma operating primarily in Greater China. Solasia's commercialization partner for Sancuso across China and Asia. Both focus on specialty therapeutics distribution in Asia with partner-driven models.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Solasia Pharma social profiles

Digital presence

Solasia Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Solasia Pharma leadership team

Management profile

Number of profiles

Profiles16 records

Solasia Pharma subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Solasia Pharma funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Solasia Pharma M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Solasia Pharma

What does Solasia Pharma do?

Solasia Pharma is a specialty pharmaceutical company that in-licenses oncology drug candidates and medical devices, advances them through clinical development and regulatory approval in Asia, and commercializes them through regional distribution partners. Its commercial portfolio includes episil oral liquid (a Camurus FluidCrystal-based medical device for oral mucositis pain), DARVIAS injection (darinaparsin for relapsed/refractory PTCL), and Sancuso (a transdermal granisetron patch for chemotherapy-induced nausea and vomiting).

Is Solasia Pharma a public or private company?

Solasia Pharma is a public company. It is classified as public and is currently operating.

When was Solasia Pharma founded?

Solasia Pharma was founded in 2006. It employs 11 to 50 people.

Where is Solasia Pharma based?

Solasia Pharma is headquartered in Minato, Japan, in the Asia region.

How does Solasia Pharma make money?

Five revenue lines are on record. Product Sales are the primary driver. The others are signing Fee / Contract Upfront, development Milestones, commercial Milestones and royalties.

Who are Solasia Pharma's main competitors?

Emerging players on record are Camurus AB and Isofol Medical AB. Direct peers are Sosei Group / Nxera Pharma, Zeria Pharmaceutical Co., Ltd., AnGes, Inc., Mochida Pharmaceutical Co., Ltd., Oncolys BioPharma Inc. and J-Pharma Co., Ltd.. Taiho Pharmaceutical is listed as a broad incumbent. Lee's Pharmaceutical Holdings is listed as a regional player.

Does Solasia Pharma have an API?

No public API is recorded for Solasia Pharma.

What industry is Solasia Pharma in?

Solasia Pharma's product category is Specialty Oncology Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAA, Primary Care & General Medicine Pharmaceuticals, with a secondary code of HLAIAAAN, Pain Management & Anesthesiology Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MarketWatchSolasia Pharma 9-Mos Loss Y680.00M Vs Loss Y726.00MSolasia Pharma reported a nine-month loss of Y680 million for the period ended September 30, 2026, down from Y726 million in the same period of 2025. Revenue rose to Y346 million from Y91 million, and operating profit improved to Y676 million from Y713 million.news.cision.comSolasia acquires episil oral liquid business from CamurusSolasia Pharma K.K. has acquired the episil oral liquid business and its worldwide licensing rights from Camurus AB in a transaction announced on July 8, 2022. This agreement allows Solasia to continue developing, manufacturing, and commercializing the treatment for intra-oral pain associated with oral mucositis. Camurus will provide assistance services during a transition period ending in May 2024 while focusing on its core CNS and rare disease programs.BioSpaceSolasia Pharma: DARVIAS® Injection 135mg (Generic Name: DARINAPARSIN /Development Code: SP-02) Approved in JapanSolasia Pharma announced that DARVIAS Injection 135mg, an organoarsenic anticancer drug, was approved by Japan's MHLW for relapsed or refractory peripheral T-cell lymphoma. The approval follows a phase II study and marks Japan as the first country to approve it; Nippon Kayaku holds marketing rights.PR NewswireIsofol completes recruitment of Japanese patients in the global phase III AGENT studyIsofol Medical AB announced the completion of Japanese patient recruitment in its global Phase III AGENT study for arfolitixorin, reaching the 56-patient target required by Japan's PMDA for potential market approval in Japan. The company reached its primary recruitment goal of 440 patients in December 2020 and has now fulfilled the additional Japanese cohort requirement, with top-line results expected in H1 2022. Solasia Pharma will fund clinical development activities in Japan, handle regulatory filings, and serve as the market authorization holder responsible for commercialization if approved.PR NewswireInvitation to a conference call and webcast by Isofol in connection with the entered license agreement with SolasiaIsofol Medical AB announced it entered into a license agreement with Solasia Pharma K.K to develop and commercialize its proprietary drug candidate arfolitixorin in Japan for advanced colorectal cancer treatment. Arfolitixorin is currently being studied in a global Phase 3 AGENT trial across approximately 90 sites in the U.S., Canada, Europe, Australia, and Japan. The company has scheduled a conference call and webcast on August 13, 2020 to discuss the partnership with investors, analysts, and media.PR NewswireIsofol enters licensing agreement with Solasia to develop and commercialize arfolitixorin in JapanIsofol Medical AB entered into a licensing agreement with Solasia Pharma K.K to develop and commercialize its drug candidate arfolitixorin for metastatic colorectal cancer in Japan. Under the deal, Isofol will receive approximately $100 million (SEK 890 million) in upfront, development, regulatory, and sales-based milestone payments, plus tiered royalties on net sales in solid double-digit figures. Solasia will serve as the Market Authorization holder and be responsible for commercialization in Japan, while Isofol retains rights to arfolitixorin in the rest of the world.news.cision.comInvitation to a conference call and webcast by Isofol in connection with the entered license agreement with SolasiaIsofol announced a license agreement with Solasia Pharma to develop and commercialize its drug candidate arfolitixorin in Japan. The company invited investors to a conference call on August 13, 2020, to discuss the deal. The drug is being studied in the Phase 3 AGENT trial for colorectal cancer.PR NewswireGlobal Chemotherapy-Induced Peripheral Neuropathy (CIPN) Market, 2016-2027ResearchAndMarkets.com released a market insights report on Chemotherapy-Induced Peripheral Neuropathy covering the G8 countries from 2016 to 2027, providing epidemiology data, market size projections, and pipeline analysis for this condition with no approved therapies currently available. The G8 CIPN market is expected to grow at a CAGR of 2.94% during the forecast period, with China holding the largest market share due to higher cancer incidence. The report profiles emerging therapies including SP-04 (PledOx by Solasia), Tetrodotoxin (by WEX Pharmaceuticals), and E-52862 (by Esteve), which are anticipated to launch during 2018–2027 and drive market expansion.GlobeNewswirePledOx® shows favorable safety and tolerability profile in the SUNCIST Phase I study in Japanese subjectsSolasia reported favorable safety and tolerability results from a Phase I study of PledOx in Japanese and Caucasian volunteers. The study included 24 Japanese and 24 Caucasian subjects receiving single doses of 2-, 5-, or 10 µmol/kg or placebo. Solasia acquired exclusive development and marketing rights for PledOx in Japan, China, Korea, and Taiwan.